Future studies will focus on applying this platform to radiopharmaceutically-relevant 225Ac in vitro and in vivo studies, as we have previously demonstrated that siderocalin can be fused with antibodies and antibody fragments for the precise delivery of cargo isotopes within targeted cancer cells43. This evidence concerns the gene LCN2 and cancer.